JNJ · News · 20261022N

Competition and Market Position

JOHNSON & JOHNSON · 2026-10-22 · Importance 23 · Surprise 24

Johnson & Johnson presented real-world and clinical data for its VARIPULSE Pro and investigational OMNYPULSE pulsed-field ablation platforms at the APHRS 2026 meeting in Busan, South Korea. VARIPULSE Pro achieved 100% acute procedural success in European patients, with a 0.4% primary adverse-event rate and mean ablation time of 17.9 minutes. OMNYPULSE data showed 82.5% of patients remained free from documented atrial-arrhythmia recurrence at 12 months under stringent monitoring. Medtronic reported competing PulseSelect and Affera data, including 100% procedural success and a 0.09% major-complication rate for PulseSelect in a global registry, highlighting active competition in atrial-fibrillation and ventricular-tachycardia ablation.